| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Presentation DetailsTitle: LB-102 for acute schizophrenia in adults: efficacy and safety from a large phase 2 clinical trialPos...
Stifel analyst Paul Matteis initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Tar...
Piper Sandler analyst Yasmeen Rahimi initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Overweight rating and ann...
Leerink Partners analyst Marc Goodman initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and an...
The shares are expected to begin trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol "LBRX."
